Gene Therapy as an Emerging Treatment Approach in Wilson Disease

This episode, titled 'Gene Therapy as an Emerging Treatment Approach in Wilson Disease,' features panelists discussing the revolutionary potential of UX701 and other AAV-based gene therapies. Dr. Peter Hedera explains that because carriers of a single ATP7B mutation are asymptomatic, a treatment does not need to achieve 100% expression to restore functional copper homeostasis. However, he raises critical questions regarding the durability of these benefits, noting that because hepatocytes are dividing cells, there is a risk of losing the genetic construct over time. Furthermore, the immunogenicity of adeno-associated viruses (AAV) typically limits patients to a single "one-shot" treatment, making durability the primary focus of current clinical trials.

The conversation expands into next-generation technologies like CRISPR-Cas9 and prime editing. While these tools offer the possibility of permanent genetic correction, the experts acknowledge the immense challenge posed by the high number of unique ATP7B mutations. The panelists emphasize that the future of Wilson disease management will likely move away from a "one size fits all" model toward a highly individualized approach. This could involve tailoring choices between traditional chelation, once-daily salts, or gene therapy based on a patient's lifestyle, their ability to adhere to complex regimens, and their willingness to undergo short-term immunosuppression for long-term freedom from daily pills.

As the segment concludes, the panel highlights that while current trials often focus on stable patients, future research may investigate whether gene therapy can accelerate recovery in acutely ill or non-compliant populations. The experts look forward to real-world evidence to determine if these emerging therapies will act as standalone cures or be integrated into hybrid treatment plans, marking an era of unprecedented granular control in medical genetics.

In the next episode, 'Real-World Evidence and Strategies for Long-Term Adherence in Wilson Disease,' panelists will continue their discussion on Wilson disease and highlight the critical barriers to lifelong medication compliance. The experts examine recent real-world data regarding treatment discontinuation and discuss how practical factors—such as dosing frequency and storage requirements—significantly influence clinical outcomes and disease progression.